


CAMBRIDGE

Published on behalf of the  
**Royal College of Psychiatrists**



[www.cambridge.org/rcpsych](http://www.cambridge.org/rcpsych)



CAMBRIDGE  
UNIVERSITY PRESS

### CPD Online

- 1 **New From CPD Online**

### Cochrane Corner

- 2 **Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life: a Cochrane Review**

Anne W. S. Rutjes, David A. Denton, Marcello Di Nisio, Lee-Yee Chong, Rajesh P. Abraham, Aalya S. Al-Assaf, John L. Anderson, Muzaffar A. Malik, Robin W. M. Vernooij, Gabriel Martínez, Naji Tabet & Jenny McCleery

### Round the Corner

- 3 **Can dietary supplements maintain cognition in mid- to late-life?**  
Alexander L. W. Smith

### Articles

- 8 **Reforming fitness to plead and stand trial legislation in England and Wales**

Nuwan Galappathie & Angela Shaw

- 16 **Psychiatric assessment of adults in care proceedings**

Rajan Nathan, Ruth Scarisbrick & Gaynor Brown

- 26 **Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia**

Mark Sweeney, Eromona Whiskey, Rishi K. Patel, Derek K. Tracy, Sukhi S. Shergill & Carla M. Plymen

- 41 **Guns and psychiatry: what psychiatrists need to know**

Ann M. Mortimer

### Commentary

- 48 **Psychiatrists should tread cautiously in firearms risk assessment**

Robin Bryant

### Article

- 50 **Bordering on the bipolar: a review of criteria for ICD-11 and DSM-5 persistent mood disorders**

Jason Luty

### Commentary

- 58 **Threading a pathway through the forest of mood and personality disorders**

Peter Tyrer

### Clinical Reflection

- 61 **How should we manage bipolar II disorder in the perinatal period?**

Jennifer Powell, Manonmani Manoharan & Joanna Reed

#### Cover image

Second-generation antipsychotic medications (SGAs) have advanced the treatment of schizophrenia over the past 30 years. However, a number of potentially life-threatening cardiac side-effects associated with these treatments concern and can discourage prescribers from administering these evidence-based treatments. In this article (26–40), authors Sweeney et al provide a practical, psychiatrist-oriented understanding of the relative frequencies, mechanisms, investigations and treatments associated with these cardiac toxicities. They aim to highlight that these are relatively rare complications of an effective class of drug and to promote the advantages of early involvement of cardiologists in the psychiatric multidisciplinary team to guide the investigation and management of these conditions.

©iStockphoto/fruttipics